Study protocol for a randomised controlled trial to determine the efficacy of lisdexamfetamine for the treatment of acute methamphetamine withdrawal in inpatient settings

Introduction Harms due to methamphetamine use disorder (MAUD) are rising globally. Untreated withdrawal symptoms perpetuate the cycle of dependence and are a barrier to treatment. There is no pharmacotherapy approved for methamphetamine withdrawal. Lisdexamfetamine (LDX) dimesylate has potential as...

Cijeli opis

Bibliografski detalji

Glavni autori:	Dan I Lubman, Jonathan Brett, Andrew Carr, Paul S Haber, Adrian J Dunlop, Nicholas Lintzeris, Frances R Levin, Nadine Ezard, Rebecca McKetin, Brendan Clifford, Michael Doyle, Krista J Siefried, Nathan Taylor, Michael Christmass, Steven Shoptaw, Shalini Arunogiri, Liam S Acheson, Mark Donoghoe, Jack Nagle
Format:	Artigo
Jezik:	Inglês
Izdano:	BMJ Publishing Group 2025-11-01
Serija:	BMJ Open
Online pristup:	https://bmjopen.bmj.com/content/15/11/e107242.full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!